Skip to main content

BP Stock Doesn’t Deserve Any of Your Investing Capital

BP Stock Doesn’t Deserve Any of Your Investing CapitalBoth the supply and demand sides of the equation spell trouble for Big Oil today. Holders of BP (NYSE:BP) stock have suffered staggering losses amid the energy-sector rout. Some audacious traders might wonder if this is the time to grab some cheap shares and hope for the best.Source: FotograFFF / Shutterstock.com That's an ill-advised strategy.Russia and Saudi Arabia are embroiled in a vicious oil-price war. The coronavirus from China is pummeling demand. There's little hope for a swift recovery in BP stock, and the prospect of a dividend cut only makes the future look bleaker. Yet, even while BP should be cutting costs, the company's new chief executive is proposing a major vision shift that could cost the company billions.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Big Plans, Few DetailsBernard Looney, who has only been BP's chief executive since February, has already made the headlines with an ambitious plan. It's probably the boldest clean-energy plan of any oil company. Evidently, Looney wants all of BP's fuel "to be de-carbonized" by 2050.This is not the appropriate forum to debate the merits of clean energy. Rather, the focus is on whether this proposal is what is best for the company and its shareholders. In any case, Looney is unambiguous in his advocacy of carbon-free energy solutions. He declared, "The world's carbon budget is finite and running out fast; we need a rapid transition to net zero … We have got to change -- and change profoundly." * 7 Buyout Targets to Watch for in 2020 It has been said that the devil is in the details. Regrettably, Looney has few details to offer in this instance. "I appreciate you want more than a vision -- you want to see milestones, near-term targets, some ways to measure progress … We do not have those for you right now," he stated.This is a time when energy companies need to cut costs just to remain solvent. BP and other oil stocks are in a terrible, sustained bear market. The oil-price suppression tug-of-war between Russia and Saudi Arabia could go on for a while. The coronavirus could continue to depress gasoline demand for many more months.This is a time for fiscal discipline, not plans that could potentially cost billions of dollars. Worse yet, we don't have a picture of how many billions it would cost since Looney hasn't provided the essential details of the plan. Dividend Cuts a PossibilityWith oil companies in survival mode, it's hard to imagine things getting any worse. Yet, the situation for BP could worsen if the company cuts its dividend. The company's generous forward dividend yield of 10% is one of the few consolation prizes for battered shareholders.Slashing that yield would likely scare off some stockholders. And that would push the price down even further into the abyss. That's a grim prospect. However, as explained by Nick Stansbury, head of commodity research at Legal & General Investment Management, given the supply and demand pressures placed on the company, it's hard to imagine BP staving off the inevitable for much longer:"The situation as it stands looks pretty challenged for most of the oil majors, if you were to assume that prices will persist at these levels … If it sticks for six, nine months, then there will be serious questions raised about the sustainability of dividends."BP's chief executive may try to avoid dividend cuts for a while. After all, Looney is new to the position and, as AJ Bell Plc. asset manager Russ Mould observes, a dividend cut is "a decision no CEO wants to be associated with … It can cost you your job." How long Looney can delay dividend cuts, and how long he gets to keep his job, remains to be seen. The Final Word on BP StockIt's questionable whether BP can embark on a likely very costly carbon-elimination plan, while avoiding cutting dividends, amid a horrendous supply and demand shock. BP stock investors could learn the hard way that in the harsh commodities business, you can't have your cake and eat it too.Louis Navellier had an unconventional start, as a grad student who accidentally built a market-beating stock system -- with returns rivaling even Warren Buffett. In his latest feat, Louis discovered the "Master Key" to profiting from the biggest tech revolution of this (or any) generation. Louis Navellier may hold some of the aforementioned securities in one or more of his newsletters. More From InvestorPlace * America's Richest ZIP Code Holds Wealth Gap Secret * 10 Stocks to Buy That Will Benefit From Coronavirus Mayhem * 5 Bank Stocks to Buy Now Because This Isn't 2008 Again * 12 Stocks to Buy That Are Already Positive The post BP Stock Doesn't Deserve Any of Your Investing Capital appeared first on InvestorPlace.




from Yahoo Finance https://ift.tt/2UHidoA

Comments

Popular posts from this blog

Photo finish: Crashing sales force Olympus to sell iconic camera business

Sometimes, the vicissitudes of capitalism force companies to exit the businesses for which they’re best known. Olympus, once a leading light in the photography industry, is now joining that list. On Wednesday, the company said it planned to quit its 84-year-old camera business. The imaging giant, known for its once-pervasive digital cameras, agreed to sell off the declining unit by year’s end. Japan Industrial Partners, a private equity firm best known for buying Sony’s struggling Vaio computer line in 2014, agreed to purchase the business. Terms of the deal were not disclosed. A glance at Olympus’s financial statements provides all the rationale for the divestiture; as at rival manufacturers, camera sales have plummeted over the past decade. For the fiscal year ended March 31, Olympus’s camera unit declined 10% versus the year prior to  ¥43.6 billion, or $407 million. The unit’s sales have collapsed by three-quarters from a decade ago, when the company brought in ¥175 billion, or $

WHO says common steroids can slash death risk for the sickest coronavirus patients

Our mission to help you navigate the new normal is fueled by subscribers. To enjoy unlimited access to our journalism,  subscribe today . An old drug can learn new tricks during the coronavirus pandemic. That’s the main takeaway from the World Health Organization (WHO) in a new analysis of corticosteroids—a class of drugs which have existed for dozens of years and are far cheaper than new, experimental COVID treatments in development—suggesting that drugs like dexamethasone can slash the chances of COVID-19 related deaths by as much as 35% in the sickest patients. The WHO analysis of coronavirus drugs encompassed seven separate studies. And while an analysis of this sort—what’s called a “meta-analysis”—isn’t as rigorous as other types of trials like a randomized controlled study, the data are compelling. Corticosteroids have a very different action mechanism from many of the other coronavirus drugs in development. COVID-19 is a peculiar disease. Some who have been infected may be